The lowa Oncology Research Association (lORA) is a multidisciplinary consortium of nine lowa hospitals, eighteen gynecologic, medical, pediatric, radiation, and surgical oncology practices and 72 physicians. In addition to the operations office in Des Moines, the lORA has four affiliate sites located in Ames, Council Bluffs, Mason City and Ottumwa and a pediatric component located at the Blank Children's Hospital in Des Moines. The lORA has been a principal member of the North Central Cancer Treatment Group (NCCTG) since 1979 and has secondary research base relationships with the Eastern Cooperative Oncology Group (ECOG), National Surgical Adjuvant Breast and Bowel Project (NSABP), Gynecologic Oncology Group (GOG), Comprehensive Cancer Center Wake Forest University (CCCWFU), and the Children's Oncology Group (COG). The lORA also actively participates in other non-member research base studies through the Cancer Trials Support Unit (CTSU). The goals of lORA are: 1) Provide excellence in cancer care to patients and families through participation in high quality cancer research;2) Support the goals and work of research bases with involvement of lORA investigators, research staff, and patient populations;3) Increase public and professional awareness of clinical trials through community outreach efforts and collaboration with other medical providers in the community;4) Increase accrual in cancer control studies by building on prior recruitment strategies implemented in previous cancer control/cancer prevention studies;5) Develop strategies to increase clinical trial participation i minority groups and the underserved population in rural areas;6) Collaborate with local health care institutions to increase participation in correlative and translational biospecimen studies.
The lORA has a proven track record as an efficient and disciplined team from five strategically located lowa communities. The organization is the link between clinical trials and a significant portion of the state of lowa with a catchment area that includes 59 counties and 50% of the state's population. The lORA will continue to enthusiastically emphasize quality in its research efforts and collaborate with local resources to promote clinical trial participation.
|Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005|
|Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27|
|Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9|
|Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76|
|Atherton, Pamela J; Halyard, Michele Y; Sloan, Jeff A et al. (2013) Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer 21:1193-9|
|Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92|
|Barton, Debra L; Liu, Heshan; Dakhil, Shaker R et al. (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105:1230-8|
|Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92|
|Laack, Nadia N; O'Neill, Brian Patrick; Ballman, Karla V et al. (2011) CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys 81:476-82|
|Barton, Debra L; Atherton, Pamela J; Bauer, Brent A et al. (2011) The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol 9:24-31|
Showing the most recent 10 out of 141 publications